Delivery Order SPE2DB24D1205-SPE2DB24FCRHV
Award Date 5/15/24
Potential Completion Date 6/6/24
Potential Value $23K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564133145 OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract has a ceiling value of $46,236.16 and runs through April 22, 2024. This delivery order falls under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00 and a...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The $23,118.08 firm fixed-price contract does not have a set-aside designation and has a period of performance through July 16, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $115,590.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide OCREVUS 300 mg/10 ml vials with a completion date of March 20, 2024. This contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $23,118.08 contract has a June 3, 2024 ultimate completion date. This award is made under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 300 mg/10 mL vials of the pharmaceutical product OCREVUS. The contract has a potential value of $34,677.12 and a completion date of March 7, 2024. This delivery order falls under a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 mg/10 mL vials. The delivery order, valued at $23,118.08, has an ultimate completion date of April 22, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58 and runs through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $48,077.16. This is a firm fixed-price delivery order with an ultimate completion date of October 9, 2025, and represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...